Time for Action: Investing in Health Canada
Recent data reveals a troubling trend: Health Canada is taking longer to assess generic and biosimilar drug submissions, delaying cost-saving prescription medications and increasing costs for Canadian taxpayers and patients.
The number and complexity of drug submissions have been increasing, but resources for Health Canada's drug review programs have remained largely static and underfunded.
Regulators in other countries have made strategic hiring investments to meet increased demands and maintain predictable business operations.
As the federal government prepares to unveil its budget, it is vital to address these delays through strategic investments in Health Canada's resources and staffing.
The issue is pressing, with significant implications for Canadian taxpayers and patients.
Author's summary: Investing in Health Canada to accelerate access to medications.
More News
- Eglin battalion chief and wife lose Crestview home to lightning strike, community rallies in support
- Comment | A spate of dealer anniversaries offers hope amid art market doomerism
- Time for Action: Investing in Health Canada to Accelerate Access to…
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- Islamic Heritage Month event in Cornwall showcases how to build community
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Thunderstorms with damaging winds and penny-sized hail in Central West Florida Monday – wind gusts up to 60 mph
- Zorin OS Breaks Download Record as Windows 10 Users Seek Alternatives
- MCU: Jeremy Allen White Responds to Popular X-Men Fan Casting
- Sweden’s still ahead in the preparedness game — and now it means business